恩度联合化疗治疗晚期难治性乳腺癌的疗效与安全性分析

目的 探讨恩度联合化疗治疗晚期难治性乳腺癌的疗效及安全性.方法 回顾性分析34例接受恩度联合化疗治疗的晚期难治性乳腺癌患者的临床资料,评估恩度联合化疗的临床疗效、无进展生存时间(PFS)和不良反应.结果34例晚期难治性乳腺癌患者均可评价疗效,治疗的客观缓解率为17.6%(6/34),疾病控制率为67.6%(23/34),中位PFS为4.04个月(2.59~5.50个月),1年生存率为59.6%,死亡11例.单因素分析及多因素分析结果显示:各临床病理特征亚组间PFS、OS比较,差异均无统计学意义(P﹥0.05).本研究主要不良反应表现为乏力及血液学毒性,经治疗均可缓解.结论 恩度联合化疗对晚期难治性乳腺癌有一定疗效,且不良反应可耐受.

Efficacy and safety of Endostar combined with chemotherapy for refractory metastatic breast cancer

Objective To discuss the efficacy and safety of Endostar in combination with chemotherapy for patients with aggressive and refractory metastatic breast cancer(MBC).Method We retrospectively analyzed the clinical data of 34 advanced MBC patients that were treated with Endostar combined with chemotherapy so as to evaluate the clinical effi-cacy,progression free survival(PFS)and adverse effects.Result 34 patients with refractory MBC were evaluable,the objective response rate (ORR) was 17.6%, and disease control rate (DCR) was 67.6%, with median PFS being 4.04 months(2.59-5.50 months),and 1-year survial rate being 59.6%,there were 11 cases of death.Univariate and multivariate analysis showed that there were no statistically significant difference regarding PFS and OS among subgroups with dis-similar clinicopathological characteristics (P>0.05). The main adverse effect was fatigue and hematological toxicities, which were resolved after treatment.Conclusion Endostar combined with chemotherapy is fairly effective and tolerable for patients with refractory metastatic breast cancer.